Cassava Sciences Inc vs Vanguard Real Estate Index Fund ETF — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Vanguard Real Estate Index Fund ETF trades at $97.22. The key difference: Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | VNQ | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | — |
52-Week High | $4.64 | $100.95 |
52-Week Low | $0.87 | $87.00 |
Enterprise Value | -$34.93M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
VNQ, the Vanguard Real Estate ETF, trades at $97.13, up 0.02% on the day, with a bearish technical signal driven by moving averages and neutral oscillators. The ETF offers a dividend of $0.86 scheduled for June 2026, but key valuation ratios like P/E and P/B are unavailable. Recent news highlights institutional selling and comparisons with global real estate ETFs, emphasizing VNQ's U.S. REIT focus and low fees.
Outlook: VNQ faces headwinds from bearish technicals and institutional outflows, but its low expense ratio and U.S. real estate exposure provide stability. Risks include interest rate sensitivity and underperformance versus broader markets, as noted in long-term return comparisons. Investors should weigh dividend income against sector volatility and macroeconomic factors.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →